Reporting owner · CIK 0001818701

MPM BioVentures 2018 GP LLC

Visual SEC Form 4 history across 2 companies, 16 transactions and 3 filings.

10%Entrada Therapeutics, Inc.
Open-market mix
Latest filingAug 31, 2026, 10:26 PM
Filings3Form 4 records
Buying$20M1 purchases
Selling$1.1M6 sales
Net value$19MBuys minus sells
Companies24 securities
Most recentAug 31, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1050-5-101Jan 266Aug 26

Net value flow

Buys minus sells

Jan 26
$20M
Aug 26
−$1.1M

Transaction texture

Ownership and ticket size

Average P/S size$3M
Median P/S size$200K
Direct0
Indirect16
Aug 31, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Cluster Buypattern1Cluster Sellingpattern6Derivative Transactionfiling-context3Large Buysize1Large Holdings Increaseholdings4Repeat Sellerpattern510% Owner Buyrole1

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Review SEC filing
Latest buy

buy at Aktis Oncology, Inc. on Jan 12, 2026 valued at $20,029,986.

Review SEC filing
Latest sale

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Review SEC filing

Associated companies

Visual map of known reporting history

TRDAEntrada Therapeutics, Inc.6 transactions · latest Aug 31, 2026, 10:26 PMAKTSAktis Oncology, Inc.10 transactions · latest Jan 14, 2026, 11:19 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
TRDAMPM BioVentures 2018 GP LLC
10%
sale44.2k-$30.9MS
Cluster Selling Repeat Seller
0.0%08/3108/31
TRDAMPM BioVentures 2018 GP LLC
10%
sale3.73k-$2.61MS
Cluster Selling Repeat Seller
0.0%08/3108/28
TRDAMPM BioVentures 2018 GP LLC
10%
sale38.9k-$28.0MS
Cluster Selling Repeat Seller
0.0%08/3108/27
TRDAMPM BioVentures 2018 GP LLC
10%
sale14.5k-$10.2MS
Cluster Selling Repeat Seller
—08/2708/26
TRDAMPM BioVentures 2018 GP LLC
10%
sale26.5k-$19.9MS
Cluster Selling Repeat Seller
—08/2708/25
TRDAMPM BioVentures 2018 GP LLC
10%
sale21.6k-$15.8MS
Cluster Selling
—08/2708/24
AKTSMPM BioVentures 2018 GP LLC
10%
unknown1.57M—C——01/1401/12
AKTSMPM BioVentures 2018 GP LLC
10%
unknown5.91M—C
Large Holdings Increase
—01/1401/12
AKTSMPM BioVentures 2018 GP LLC
10%
unknown1.31M—C
Large Holdings Increase
—01/1401/12
AKTSMPM BioVentures 2018 GP LLC
10%
C6.00M$0C
Derivative Transaction
—01/1401/12

MPM BioVentures 2018 GP LLC Insider Activity FAQ

SEC Form 4 context

Who is MPM BioVentures 2018 GP LLC?

MPM BioVentures 2018 GP LLC is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001818701.

Which companies has MPM BioVentures 2018 GP LLC reported transactions for?

Entrada Therapeutics, Inc., Aktis Oncology, Inc.

When was MPM BioVentures 2018 GP LLC's latest insider buy?

buy at Aktis Oncology, Inc. on Jan 12, 2026 valued at $20,029,986.

When was MPM BioVentures 2018 GP LLC's latest insider sale?

sale at Entrada Therapeutics, Inc. on Aug 31, 2026 valued at $309,370.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.